Lumos Diagnostics Holdings Ltd.ASX: LDX

Lumos Secures Further US Medicare Reimbursement for FebriDx

· Issued by Lumos Diagnostics Holdings Ltd.

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Lumos Diagnostics Holdings Ltd. has announced that it secured additional Medicare reimbursement coverage for its FebriDx test from two more Medicare Administrative Contractors, enhancing its market access in the U.S. This coverage now includes four out of seven MACs, representing a significant portion of U.S. Medicare payment coverage, which is crucial for the commercial success of FebriDx. The company aims to continue negotiations with the remaining MACs and pursue private payor reimbursement to achieve nationwide access for patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Lumos Diagnostics Holdings Ltd. on 6ix

Story so far

Earlier from Lumos Diagnostics

Later from Lumos Diagnostics

All Lumos Diagnostics news releases